Prothena Corporation plc (PRTA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $409.26M
Last updated: Nov 17, 2026 at 4:15 PM ET
Prothena Corporation plc (PRTA) Stock Chart
Prothena Corporation (PRTA) has a latest price of $8.26 on Nov 17, 2026, 30.0% below its 52-week high of $11.80. Its price fell 16.8% over the past 12 months. The month-end price fell 82.3% over the 10 years through Oct 2026, a compound annual decline of 15.9%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $71.23 in Sep 2021 and its lowest $4.59 in May 2025, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart PRTA with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for PRTA.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 11.1%, and over 6 months it fell 8.9%. The month-end price fell 76.8% over the 3 years through Oct 2026, a compound annual decline of 38.5%.
| Period | Change |
|---|---|
| 1 month | -2.6% |
| 3 months | -11.1% |
| 6 months | -8.9% |
| 12 months | -16.8% |
| 12 months, with dividends | -16.8% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -76.8% | -38.5% |
| 5 years | -84.7% | -31.3% |
| 10 years | -82.3% | -15.9% |
Price by Year
Its best calendar year was 2021, when the price rose 311.3%, and its weakest was 2018, when it fell 72.5%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $8.47 | -11.3% |
| 2025 | $9.55 | -31.0% |
| 2024 | $13.85 | -61.9% |
| 2023 | $36.34 | -39.7% |
| 2022 | $60.25 | +22.0% |
| 2021 | $49.40 | +311.3% |
| 2020 | $12.01 | -24.1% |
| 2019 | $15.83 | +53.7% |
| 2018 | $10.30 | -72.5% |
| 2017 | $37.49 | -23.8% |
Trading Range
The price is 2.6% below its 50-day average of $8.48 and 9.9% below its 200-day average of $9.17.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $8.26 | |
| 52-week high | $11.80 | -30.0% |
| 52-week low | $7.73 | +6.9% |
| 50-day average | $8.48 | -2.6% |
| 200-day average | $9.17 | -9.9% |
Price Risk
Over 3 years, its largest fall from a peak was 88.7%.
| Measure | Value |
|---|---|
| 1-year beta | 1.06 |
| Largest fall, 1 year | -31.5% |
| Largest fall, 3 years | -88.7% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About PRTA
What is PRTA's 1-year price change?
Prothena Corporation's price fell 16.8% over the past 12 months. With dividends included, the 12-month total return was -16.8%.
What is PRTA's 5-year price change?
Prothena Corporation's month-end price fell 84.7% over the 5 years through Oct 2026, a compound annual decline of 31.3%. These figures leave out dividends.
What is PRTA's 52-week high and low?
Prothena Corporation's 52-week high is $11.80 and its 52-week low is $7.73. Its latest price of $8.26 on Nov 17, 2026 is 30.0% below the high.
What is PRTA's beta?
Prothena Corporation's 1-year beta against the S&P 500 is 1.06, so its price has moved about in line with the market over the past year. Its largest fall from a peak over the past year was 31.5%.
Is the PRTA chart free?
Yes. Advanced Charting for PRTA is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
PRTA pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors